Gangnam Severance Hospital
- Country
- š°š·South Korea
- Ownership
- Private
- Established
- 1983-04-01
- Employees
- -
- Market Cap
- -
Clinical Trials
137
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (109 trials with phase data)ā¢ Click on a phase to view related trials
Axillary Nodal Burden in HER2+ and TNBC
- Conditions
- Breast Cancer
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 1571
- Registration Number
- NCT07211451
- Locations
- š°š·
Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Please Select, South Korea
Comparison of Safety and Clinical Effects of Straight and Articulated Instruments (ArtiSential) in Laparoscopic Gastrectomy for Gastric Cancer Patients, a Prospective Randomized Study
- Conditions
- Gastric Adenocarcinoma Patients, Who Are Scheduled for Laparoscopic Radical Gastrectomy
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT07100431
- Locations
- š°š·
GangnamSeverance Hospital, Seoul, Korea, Republic of
Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score
- Conditions
- Breast CancerTumor Grade
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 4000
- Registration Number
- NCT07093775
Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT07025460
- Locations
- š°š·
Institutional Review Board, Gangnam Severance Hospitial Yonsei University College of Medicine, Seoul, South Korea
Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC
- Conditions
- Triple-Negative Breast Neoplasm
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Gangnam Severance Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT07011823
- Prev
- 1
- 2
- 3
- 4
- 5
- 28
- Next
News
Ovarian Function Suppression Enhances Survival in Select HER2-Positive Breast Cancer
ā¢ Exploratory analysis of the HERA trial reveals that ovarian function suppression (OFS) combined with endocrine therapy significantly improves long-term survival in premenopausal women with HER2-positive, hormone receptor-positive breast cancer. ā¢ The 10-year disease-free survival rate increased from 59.6% with tamoxifen alone to 70.9% with the addition of OFS, demonstrating a substantial benefit in disease control. ā¢ Overall survival rates at 10 years also saw a marked improvement, rising from 74.0% to 84.7% with the inclusion of OFS in the treatment regimen. ā¢ While OFS can be challenging due to toxicity, its use should be considered in selected high-risk patients to improve survival outcomes.